Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Crescent Biopharma Q3 2026 Results: Net Loss of $37.7M, Loss Widens

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.10.0
Net income-37.7-24.6

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Crescent Biopharma, Inc.: key numbers

Share price
$13.50Close, Nov 16
Market cap
$525M
Shares outstanding
38.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Crescent Biopharma, Inc.

All →
4:16 PM ET 8-K
Financial Results

Crescent Biopharma Financial Results

Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.

Counterparty
Kelun-Biotech

“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”

Joshua Brumm, chief executive officer of Crescent

“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”

Joshua Brumm, chief executive officer of Crescent
4:26 PM ET 8-K
Business Update

Crescent Biopharma Business Update

Crescent Biopharma provided a comprehensive clinical pipeline update, including the commencement of chemotherapy combination cohorts in its Phase 1/2 ASCEND trial for CR-001. The company also announced the initiation of combination studies with Kelun-Biotech and set expectations for initial monotherapy data readouts in Q1 2027.

Counterparty
Kelun-Biotech Biopharmaceutical Co., Ltd.
4:03 PM ET Form 4
Insider Selling

Crescent Biopharma CMO Ellie Eunkyung Im Sells $11.2K of Stock

Ellie Eunkyung Im, CMO, sold 623 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $11.2K in total on Sep 16, 2026. Shares held after the trade: 21,446 (-2.8%).

Value
$11.2K
Shares
623
Price
$17.90
Role
CMO
Holding change
-2.8%
Trade date
Sep 16, 2026
4:03 PM ET Form 4
Insider Selling

Crescent Biopharma President and COO Jonathan McNeill Sells $77.2K of Stock

Jonathan McNeill, President and COO, sold 4,570 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.90) in 2 transactions, worth $77.2K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 134,588 (-2.8%).

Value
$77.2K
Shares
4,570
Average price
$16.90
Role
President and COO
Holding change
-2.8%
Trade date
Sep 16, 2026 to Sep 18, 2026
4:03 PM ET Form 4
Insider Selling

Crescent Biopharma CFO Richard William Scalzo Sells $10.2K of Stock

Richard William Scalzo, CFO, sold 568 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $10.2K in total on Sep 16, 2026. Shares held after the trade: 19,730 (-2.8%).

Value
$10.2K
Shares
568
Price
$17.90
Role
CFO
Holding change
-2.8%
Trade date
Sep 16, 2026
4:03 PM ET Form 4
Insider Selling

Crescent Biopharma CEO Joshua T. Brumm Sells $160K of Stock

Joshua T. Brumm, CEO, sold 9,447 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.91) in 2 transactions, worth $160K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 271,765 (-2.8%).

Value
$160K
Shares
9,447
Average price
$16.91
Role
CEO
Holding change
-2.8%
Trade date
Sep 16, 2026 to Sep 18, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.